

# The selection and use of essential in vitro diagnostics

---

Report of the third meeting of the WHO Strategic Advisory Group of  
Experts on In Vitro Diagnostics, 2020  
(including the third WHO model list of essential in vitro diagnostics)



The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO *Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int); order on line: [www.who.int/bookorders](http://www.who.int/bookorders)).

W H O T e c h n i c a l R e p o r t S e r i e s  
1 0 3 1

# The selection and use of essential in vitro diagnostics

---

Report of the third meeting of the WHO Strategic Advisory Group of  
Experts on In Vitro Diagnostics, 2020  
(including the third WHO model list of essential in vitro diagnostics)



**World Health  
Organization**

The selection and use of essential in vitro diagnostics: report of the third meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2020 (including the third WHO model list of essential in vitro diagnostics).

(WHO Technical Report Series, no. 1031)

ISBN 978-92-4-001910-2 (electronic version)

ISBN 978-92-4-001911-9 (print version)

ISSN 0512-3054

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** The selection and use of essential in vitro diagnostics: report of the third meeting of the WHO Strategic Advisory Group of Experts on In Vitro Diagnostics, 2020 (including the third WHO model list of essential in vitro diagnostics). Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1031). Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

# Contents

<b>Abbreviations</b>	vii
<b>List of participants</b>	xiii
<b>Declarations of interests</b>	xvi
<b>Acknowledgements</b>	xvii
<b>Introduction</b>	1
<b>1. EDL and the review process</b>	2
1.1. The EDL so far	2
1.2. Methods used to develop EDL 3	3
1.2.1. Changes to submission forms	4
1.2.2. 2020 remote process for deliberations	4
<b>2. EDL-related products and processes</b>	7
2.1. Progress updates	7
2.1.1. eEDL	7
2.1.2. Country guidance	8
2.1.3. EDL technical specifications	8
2.1.4. Harmonization activities	9
2.2. Prioritization of the EDL	10
<b>3. Applications for additions to the EDL</b>	13
EDL Section I.a: General IVDs for community settings and health facilities without laboratories	14
3.1. Erythrocyte sedimentation rate	14
EDL Section I.b: Disease-specific IVDs for community settings and health facilities without laboratories	21
CORONAVIRUS DISEASE	21
3.2. SARS-CoV-2 antigen	21
SICKLING DISORDERS	28
3.3. Sickle cell testing	28
STREPTOCOCCAL PHARYNGITIS	36
3.4. Group A <i>Streptococcus</i> antigen	36
EDL Section II.a: general IVDs for use in clinical laboratories	42
HAEMATOLOGY	42
3.5. Cerebrospinal fluid profile: leukocyte count, differential leukocyte count, protein and glucose	42
EDL Section II.b: Disease-specific IVDs for clinical laboratories	55
ASPERGILLOSIS	55
3.6. <i>Aspergillus</i> antigen	55
3.7. <i>Aspergillus</i> immunoglobulin G antibody	62
CANCER	67
3.8. Serum and urine protein electrophoresis for multiple myeloma	67
3.9. Epidermal growth factor receptor gene mutation	72

CORONAVIRUS DISEASE	81
3.10. SARS-CoV-2 nucleic acid test	81
ENDOCRINE DISORDERS	89
3.11. Cortisol (total)	89
3.12. Estradiol	106
3.13. Follicle-stimulating hormone	116
3.14. Luteinizing hormone	128
3.15. Progesterone	139
3.16. Prolactin	148
NEGLECTED TROPICAL DISEASES	160
3.17. <i>Trypanosoma</i> immunoglobulin G antibody	160
3.18. Visceral leishmaniasis direct agglutination test	166
PNEUMOCYSTIS PNEUMONIA	174
3.19. <i>Pneumocystis jirovecii</i> nucleic acid test	174
PRIMARY IMMUNODEFICIENCIES	182
3.20. Serum and urine protein electrophoresis for primary immunodeficiency	182
STREPTOCOCCAL PHARYNGITIS	190
3.21. Group A <i>Streptococcus</i> nucleic acid test	190
VACCINE-PREVENTABLE DISEASES	195
3.22. Measles immunoglobulin G antibody	195
3.23. Measles immunoglobulin M antibody	201
3.24. Measles nucleic acid test	207
3.25. Rubella immunoglobulin G antibody	213
3.26. Rubella immunoglobulin M antibody	219
<b>4. Applications for revisions to the EDL</b>	<b>226</b>
CLINICAL CHEMISTRY	226
4.1. Changes requested by SAGE IVD	226
HEPATITIS B	226
4.2. Hepatitis B e antigen	226
HIV INFECTION	227
4.3. Qualitative HIV virological nucleic acid test	227
TUBERCULOSIS	228
4.4. Lipoarabinomannan antigen	228
BACTERIOLOGY, MYCOLOGY AND PARASITOLOGY	229
4.5. Changes requested by SAGE IVD	229
CLINICAL CHEMISTRY	229
4.6. Changes requested by SAGE IVD	229
4.7. C-reactive protein	230
4.8. Creatinine	230
4.9. Glucose-6-phosphate dehydrogenase activity	231
HAEMATOLOGY	231
4.10. Changes requested by SAGE IVD	231
4.11. Complete blood count automated	232
CLINICAL PATHOLOGY (NEW SECTION)	232
4.12. Changes requested by SAGE IVD	232
SEROLOGY	232
CANCER	233
4.13. Alpha-fetoprotein	233

4.14. Basic panel for immunohistochemistry testing for diagnosis of lymphoma	234
4.15. Basic panel of immunohistochemical markers for diagnosis of solid tumours	235
4.16. Essential flow cytometry panel of antibodies for leukaemia	238
4.17. Basic panel of immunohistochemical markers for diagnosis of solid tumours	239
4.18. Tyrosine-protein kinase receptor or human epidermal growth factor receptor 2 overexpression	240
4.19. Lactate dehydrogenase activity	240
HEPATITIS B	243
4.20. Quantitative HBV virological nucleic acid test	243
HEPATITIS C	243
4.21. Qualitative or quantitative HCV virological nucleic acid test	243
HIV INFECTION	244
4.22. Quantitative HIV virological nucleic acid test	244
HUMAN PAPILLOMAVIRUS INFECTION	245
4.23. Human papillomavirus nucleic acid test	245
PRIMARY IMMUNODEFICIENCIES	245
4.24. Lymphocyte subtype enumeration	245
SEXUALLY TRANSMITTED INFECTIONS	246
4.25. Qualitative test for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> infections	246
TUBERCULOSIS	247
4.26. <i>Mycobacterium tuberculosis</i> DNA nucleic acid test	247
4.27. <i>Mycobacterium tuberculosis</i> DNA loop-mediated isothermal amplification	248
4.28. <i>Mycobacterium tuberculosis</i> DNA mutations associated with resistance	249
OTHER TRANSFUSION-TRANSMITTED ORGANISMS	249
4.29. IVDs to screen for pathogens in blood donations	249
<b>5. Applications for Do Not Do recommendations in the EDL</b>	250
5.1. Commercial serodiagnostic tests to diagnose tuberculosis	250
5.2. Western blot and line immunoassays to diagnose HIV infection	251
<b>6. Applications for reversing conditional listings in the EDL</b>	254
HIV INFECTION	254
6.1. <i>Histoplasma</i> antigen test	254
NEGLECTED TROPICAL DISEASES	256
6.2. Kato-Katz test for soil-transmitted helminths and intestinal schistosomes	256
PRIMARY IMMUNODEFICIENCIES	258
6.3. Enumeration of lymphocyte subtypes: CD4, CD8, CD20 and CD16/56 cells, B cells and NK cells	258
6.4. Immunoglobulin plasma levels	260
6.5. Zika virus immunoglobulin M	262
<b>7. Summary and recommendations</b>	265
7.1. IVDs adopted for EDL 3	265
7.1.1. Additions and revisions	266
7.1.2. Do Not Do recommendations	268
7.1.3. Rejections	268
7.2. IVDs recommended for EDL 4	269
7.2.1. New submissions	269
7.2.2. Additional evidence	270

7.3. General recommendations	271
7.3.1. EDL format	271
7.3.2. EDL processes	271
7.3.3. EDL-related products	271
7.3.4. EDL strategy	272
<b>Annex 1</b>	273
The third WHO model list of essential in vitro diagnostics (EDL 3)	273
<b>Index</b>	353

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>